An Usher of Immunology Biosimilars in the Next 5 Years? Biosimilars are biologic medicines that are highly similar to existing licensed biologic products with no
Generics for Otezla® to be out in the United States in February 2028 Amgen’s oral phosphodiesterase-4 (PDE-4) inhibitor – Otezla® (Apremilast) is approved in the
Inflation Reduction Act: Patients sigh relief but confusion for biosimilar manufacturers The Inflation Reduction Act of 2022 (IRA) was signed into law in the United
First generic of Vyvanse® launched in the United States Vyvanse® (Lisdexamfetamine dimesylate), a schedule C-II controlled substance, was approved by the U.S. Food and Drug Administration
Stelara® Biosimilars: Relief for plaque psoriasis patients Johnson & Johnson’s (J&J) plaque psoriasis blockbuster drug, Stelara® (Ustekinumab), gained its first approval from U.S. FDA in September 2009.
